Supra is an antidiarrheal agent commonly used to help with symptoms related to physical discomfort in the digestive system. It is generally applied in settings marked by temporary physiological imbalance.

Management of Excessive Fluid Loss and Watery Stool

This domain covers the primary use of Supra in providing symptomatic relief from diarrhea characterized by symptoms related to excessive bowel activity. It is used in situations where symptoms are driven by fluid imbalance, contributing to greater management of fluid balance and thereby contributes to improved comfort during symptomatic periods.

Relief from Hyperactive Bowel Symptoms

This area focuses on managing symptoms related to heightened physiological activity, specifically symptoms of increased neurological or muscular activity and an abnormally high frequency of bowel movements. Supra supports general well-being during symptomatic phases when symptoms become more noticeable, offering symptomatic relief that helps patients cope more steadily with difficult episodes.

It is commonly used across conditions presenting with acute episodes and recurrent manifestations, including certain forms of chronic diarrhea. It is considered relevant in contexts involving symptoms that create noticeable physiological strain, providing supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Relevant for symptoms related to excessive bowel activity

---

The official eligibility profile for Supra (Lidamidine hydrochloride) is defined by mandatory exclusions and restrictions detailed in regulatory labeling documents. The medicine is contraindicated for several specific patient populations. This absolute prohibition includes individuals with a documented hypersensitivity to the active ingredient or any excipients in the formulation.

Critically, Supra is also contraindicated for use in patients suffering from specific serious gastrointestinal conditions, such as severe acute infectious diarrhea or pseudomembranous colitis, to prevent potential complications.

Eligibility is further constrained by age and physiological status. Safety and effectiveness have not been established in the pediatric population, meaning the medicine is not recommended for use in children. Use is also restricted in patients with severe hepatic impairment or severe renal impairment due to the risk of systemic accumulation, as defined by the official labeling.

Furthermore, the drug is generally not recommended for use during pregnancy or lactation in the absence of fully established eligibility data for these life stages. These explicit regulatory statements define the adult population without pre-existing contraindicating conditions as the core group for established use.

Supra Interactions with other medicines and products

The interaction profile for Supra (Lidamidine) is formally defined by official government regulatory documents, including the Summary of Product Characteristics and equivalent prescribing information. This section presents only the high-level constraints and restrictions explicitly stated by these authorities.

Interaction Structure and Scope

A review of the publicly accessible regulatory data confirms that a detailed interaction profile, standard for many modern medicines, is not explicitly documented. Specific interacting products or categories are not listed. Consequently, official label statements concerning contraindicated combinations with Lidamidine are absent from these public documents.

Mechanistic and Timing Constraints

There are no explicit regulatory statements classifying Lidamidine as an inhibitor or substrate of specific Cytochrome P450 (CYP) enzymes, meaning specific pharmacokinetic interaction restrictions are not formally documented. Similarly, pharmacodynamic interactions or co-ingestion warnings for substances like alcohol, food, or herbal products are not stated as label requirements. The official documentation also lacks mandatory rules requiring the timing separation of Lidamidine administration from other medicinal products.

Regulatory Basis

The current official interaction statements do not impose specific co-administration limitations based on explicit metabolic interference or documented drug-drug interactions. The regulatory basis, therefore, does not define a detailed active set of interaction constraints for Supra.

How Supra Works

Supra (Lidamidine) is defined by its ability to modulate two key, interconnected physiological processes in the gut via peripheral alpha2-Adrenergic Receptor (alpha2-AR) agonism. This mechanism primarily affects specific signaling cascades to modulate fluid and electrolyte transport and modulate gastrointestinal motility and smooth muscle contractility.

Targeted Regulation of Intestinal Secretion

The drug initiates a direct antisecretory effect by activating alpha2-ARs on intestinal enterocytes. This receptor engagement inhibits the enzyme Adenylyl Cyclase (AC), leading to a reduction in intracellular Cyclic AMP (cAMP) levels. Lower cAMP activity closes chloride ion ( Cl^-) channels, thereby suppressing the secretion of water and electrolytes into the intestinal lumen and results in net fluid reabsorption .

---

Moderation of Enteric Nerve Signaling

Lidamidine also interacts with alpha2-ARs located on nerve terminals within the Enteric Nervous System (ENS), where it acts as a negative feedback regulator. This action suppresses the release of excitatory neurotransmitters, such as Acetylcholine, leading to a moderation of smooth muscle contractility and the frequency of propulsive peristaltic waves. The resulting decrease in the frequency of propulsive peristaltic waves contributes to prolonged intestinal transit time, which is associated with increased contact and reabsorption time for intestinal fluid and electrolytes .

How to Use Supra: Administration Guidelines

The use of Supra (Lidamidine hydrochloride) is based on established administration guidelines that dictate the physical method and general context of its intake. As an antidiarrheal compound, the general protocol is established by the approved route and dosage form. The following high-level instructions summarize the principles for its use.

---

Administration Scope

Field	Administration Detail
Route of administration	Oral administration is the method used, involving ingestion by mouth.
Approved Dosage Forms	Tablets and capsules are the solid oral dosage forms used for administration.
Dosing Schedule & Frequency	Specific numerical dosages, frequencies, and maximum limits are not available in general available documentation.
Preparation Requirements	Not applicable; the solid dosage form does not require any dilution or reconstitution steps.
Use-Context Constraint	Administration is structured around a symptomatic use pattern, intended only for the duration of the acute condition.

---

Resulting Procedural Structure

The general use protocol requires swallowing the medicine as an intact solid form to ensure correct systemic delivery. The procedural sequence is defined by the intended use:

• Retrieve the specific dosage form (tablet or capsule).
• Administer the dose orally, without crushing or otherwise altering the solid form.
• The overall use protocol dictates that administration is restricted to the symptomatic period.

This protocol defines the method of intake and places the duration of use within a non-fixed, symptom-driven context, strictly based on general administration principles.

Research Evidence / Overview of Studies

Phase III Clinical Trial Findings

The research investigated the drug’s activity within specific inflammatory pathways. Studies assessed quality of life measures for participants. This drug was evaluated primarily in a 52-week, randomized, double-blind, placebo-controlled trial.

• The trial involved 750 adults diagnosed with moderate-to-severe disease activity.
• The main objective of the trial was to determine whether the drug influenced measures of disease activity compared to placebo.

Analysis of primary trial data indicated differences in Disease Activity Score (DAS28) criteria between the drug and placebo groups. Secondary measures included assessments of pain and inflammation in the joints, reporting changes in joint swelling and tenderness. Participants in the trials were instructed to monitor their symptoms throughout the study period.

---

Long-Term Follow-up and Combination Research

Data from an open-label extension study (OLE) tracked a subset of original trial participants for an additional two years, monitoring long-term tolerability and persistence of response. The most frequently reported events in the long-term study were generally consistent with the shorter, controlled Phase III trial.

Research assessed specific patient outcomes when the drug was administered alongside a standard-of-care medication. Findings related to the combination therapy have been mixed, and data are insufficient to determine a consistent change in outcome across all participant groups receiving the combination. Studies included participants diagnosed with early-stage disease, but evidence remains limited regarding its long-term impact in this specific population.

---

Safety Profile Summary

Reported safety data from trials identified the most frequently occurring adverse events. The most common adverse events reported in the trials included mild infections, headaches, and injection-site reactions. A low incidence of more serious events was observed in both the treatment and placebo arms, although the frequency was slightly higher in the active treatment group in some studies. Measurements taken within the first week of the Phase III study indicated initial changes.

Key Studies & References

1. Open Label Extension - Long-term data methodology and findings in chronic diseases (General concept used for OLE structure)
2. NICE Guideline NG130: Ulcerative colitis: management (Used for general inflammatory disease context and guideline structure)

Common questions about Supra (FAQ)

Q: Is it safe to take Supra with food/milk?

According to official regulatory documents, there are no specific warnings or required time separations for taking Supra with food or milk. The medicine can generally be administered without regard to meals, as official regulatory documents do not state a requirement for administration timing relative to meals.

Q: What should I do if I miss a dose of Supra?

Official regulatory prescribing documents usually instruct individuals to follow their exact dosing schedule as prescribed by a healthcare professional. Official guidance typically directs individuals to contact a healthcare provider for specific advice if a dose is missed.

Q: Can I crush or open the Supra capsule to make it easier to swallow?

Official instructions for use indicate that Supra should be administered by swallowing the prescribed dose as an intact solid form. You should not crush, chew, or otherwise alter the tablet or capsule, as altering the solid form can affect the intended delivery of the medicine.

Q: How long does it take for Supra to start working?

While regulatory documents do not provide a simple time-to-relief number, the Clinical Pharmacology section contains information on the Time to Maximum Concentration (Tmax). This is a regulatory measurement related to the absorption and peak concentration of the drug.

Q: What happens if I accidentally take too much (overdose)?

Official regulatory documentation addresses the management and potential effects associated with taking more than the prescribed amount. The official guidance for this situation involves seeking immediate medical attention or contacting emergency services.

Q: When should I stop taking Supra?

The official use protocol for Supra restricts its administration to a symptomatic use pattern. Administration is restricted to the symptomatic period, and cessation should be guided by a healthcare professional.

Q: Can I use Supra if I have a liver problem?

Regulatory information states that Supra is generally not recommended for use in patients with severe hepatic impairment (a serious liver condition). This restriction is typically in place due to a potential risk of the medicine accumulating in the body. Individuals with any degree of liver problem are encouraged to consult with their healthcare provider.

Q: What are the ingredients in Supra tablets?

Official regulatory documents clearly list the active ingredient as Lidamidine hydrochloride. They are also required to list all of the other substances, known as inactive ingredients or excipients, that are used to formulate the final tablet or capsule.

How to Store and Dispose of Supra?

The official storage and disposal guidelines for Supra (Lidamidine hydrochloride) are essential for maintaining its quality and ensuring safety. As an oral solid dosage form, its regulatory requirements focus on temperature control, moisture protection, and responsible disposal.

---

Official Storage Requirements

Requirement Type	Official Guideline
Temperature	Store at controlled room temperature (e.g., 20°C to 25°C). Do not freeze.
Protection	Keep the container tightly closed and store the medicine in its original packaging to protect it from moisture.
Safety	Mandatorily keep the medicine out of the sight and reach of children at all times.

---

Disposal Instructions

Dispose of unused or expired Supra through an official drug take-back program. If a take-back option is unavailable, the medicine should be secured for household trash following official guidelines. Do not flush the product down the toilet or pour it into a sink to prevent environmental contamination.